A PhaseII study of XP(capecitabine plus cisplatin) combination therapy for HER2 negative advanced/recurrent gastric cancer
Phase 2
Recruiting
- Conditions
- HER2 negative advanced/recurrent gastric cancer
- Registration Number
- JPRN-UMIN000013669
- Lead Sponsor
- SGCSG:Shimane Gstroenterological Vancer Study Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 36
Inclusion Criteria
Not provided
Exclusion Criteria
(1)Forbidden case to use capecitabine and cisplatin. (2)R1 operation(histologically positive PM, OM, LM, VM). (3)Infection or inflammatory case. (4)Severe heart disease. (5)Severe complicated case such as ileus, intestitial pneumonia, uncontrolled DM, liver cirrhosis etc. (6)Difficulty to join the trial due to psychosis nervous system damage. (7)Complicated other active cancer. (8)patient who want to be pregnant and/or pregnant woman. (9)Intend to make pregnant. (10)Active hepatitis type HB positive(HBs antigen, HBc antibody and HBs antibody). (11)Otherwise determined by investigators or site principal investigators to be unsuitable for participation in study).
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response rate
- Secondary Outcome Measures
Name Time Method Time to response, Disease control rate, Progression free survival, Time to treatment failure, Overall survival, Relative dose intensity, safety